2,3-Dihydroxy-6-nitro-7-sulfamoyl-benzo(F)quinoxaline: a Neuroprotectant for Cerebral Ischemia

19901,140 citationsJournal Article

Authors

Malcolm J. Sheardown · Ferrosan Medical Devices (Denmark)

Elsebet Ø. Nielsen · Ferrosan Medical Devices (Denmark)

Anker Jón Hansen · Ferrosan Medical Devices (Denmark)

Poul Jacobsen · Ferrosan Medical Devices (Denmark)

Tage Honoré · Ferrosan Medical Devices (Denmark)

Abstract

2,3-Dihydroxy-6-nitro-7-sulfamoyl-benzo(F)quinoxaline (NBQX) is an analog of the quinoxalinedione antagonists to the non-N-methyl-D-aspartate (non-NMDA) glutamate receptor. NBQX is a potent and selective inhibitor of binding to the quisqualate subtype of the glutamate receptor, with no activity at the NMDA and glycine sites. NBQX protects against global ischemia, even when administered 2 hours after an ischemic challenge.

Topics & Keywords

Synthesis and Biological Evaluation Phenothiazines and Benzothiazines Synthesis and Activities Ion channel regulation and function

Publication Details

Published in: Science

Volume 247, Issue 4942, pp. 571-574

DOI: 10.1126/science.2154034

Field-Weighted Citation Impact: 128.12

Command Palette

2,3-Dihydroxy-6-nitro-7-sulfamoyl-benzo(F)quinoxaline: a Neuroprotectant for Cerebral Ischemia

Authors

Abstract

Topics & Keywords

Publication Details